Reyvow ® (lasmiditan) tablets CV

50 mg, 100 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

REYVOW® (lasmiditan): Pregnancy Registry

There will be a Reyvow (lasmiditan) pregnancy registry in the United States starting in 2021.

Additional Information

A pregnancy registry for lasmiditan will be available in the United States starting in 2021.

Pregnancy or related events can be reported to

  • the Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov/medwatch, or

  • Eli Lilly and Company at 1-800-LILLYRX (1-800-545-5979).

Enclosed Prescribing Information

REYVOW® (lasmiditan) tablets, for oral use, CV, Lilly

Date of Last Review: June 10, 2020

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical